Abstract
A fixed-dose combination of the hepatitis C virus (HCV) NS5B polymerase inhibitor sofosbuvir, the HCV NS5A inhibitor velpatasvir and the HCV NS3/4A pr......
小提示:本篇文献需要登录阅读全文,点击跳转登录